INSIGHT: A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Study Details
Study Description
Brief Summary
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Ripretinib 150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles. |
Drug: Ripretinib
50 mg tablets
Other Names:
|
Active Comparator: Sunitinib 50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles. Sunitinib will be given continuously for 4 weeks with a 2-week break. |
Drug: Sunitinib
12.5 mg tablets
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression-free Survival (PFS) [Up to end of treatment; up to approximately 48 months]
The time from randomization until documented progressive disease (PD) based on IRR per mRECIST or death due to any cause, whichever occurs first.
Secondary Outcome Measures
- Objective Response Rate (ORR) [Up to end of treatment; up to approximately 48 months]
Compare ORR by IRR of ripretinib vs sunitinib using mRECIST
- Overall Survival (OS) [Up to approximately 48 months]
Compare OS of ripretinib vs sunitinib
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female ≥18 years of age.
-
Histologic diagnosis of GIST with co-occurring KIT exons 11+17/18 mutations confirmed by ctDNA sample.
-
Participants must have advanced GIST and radiologic progression on imatinib treatment.
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2 at screening.
-
Female participants of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug.
-
Participants of reproductive potential must agree to follow contraception requirements.
-
Participants must have at least 1 measurable lesion according to mRECIST v1.1 within 21 days prior to the first dose of study drug.
-
Adequate organ function and bone marrow reserve based on laboratory assessments performed at screening.
-
Resolution of all toxicities from prior therapy to Grade ≤1 (or participant baseline) within 1 week prior to the first dose of study drug.
Exclusion Criteria:
-
History of KIT exon 9 mutation or detection of KIT exon 9, 13, or 14 mutations in a ctDNA sample.
-
Has known active central nervous system metastases.
-
New York Heart Association Class II-IV heart disease, myocardial infarction within 6 months of Cycle 1 Day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or congestive heart failure.
-
Use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A prior to the first dose of study drug, and consumption of grapefruit or grapefruit juice within 14 days prior to the first dose of study drug.
-
Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug.
-
Known human immunodeficiency virus or hepatitis C infection only if the participant is taking medications that are excluded per protocol, acute or chronic hepatitis B, or acute or chronic hepatitis C infection.
-
Gastrointestinal abnormalities including, but not limited to:
-
inability to take oral medication
-
malabsorption syndromes
-
requirement for intravenous alimentation
-
Any active bleeding excluding hemorrhoidal or gum bleeding.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Deciphera Pharmaceuticals LLC
Investigators
- Study Director: Clinical Team, Deciphera Pharmaceuticals LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DCC-2618-03-003